IGC Pharma, Inc. Overview
Pro stress-test →IGC Pharma is a clinical-stage biotechnology company developing Alzheimer's disease therapeutics using artificial intelligence and pharmaceutical cannabinoids. The company's lead asset, IGC-AD1, is a cannabinoid-based therapy in Phase 2 trial (CALMA) for agitation in Alzheimer's dementia.
Strategic Profile
Pro stress-test →The CALMA trial reached approximately 70% enrollment as of February 2026, with completion expected by mid-2026 before database lock and topline results. The pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The company is positioning itself at the intersection of AI-driven drug discovery and cannabinoid therapeutics for CNS disorders.
Competitive Landscape
Pro stress-test →IGC develops advanced cannabinoid-based formulations for treating Alzheimer's disease and related conditions. Direct competitors in cannabinoid-based Alzheimer's therapeutics are limited; broader competition comes from established pharma pursuing amyloid and tau-targeting approaches (e.g., Eli Lilly, Biogen). IGC's AI-enabled discovery and first-mover status in cannabinoid agitation therapies differentiate it, though clinical efficacy remains unproven.
Industry Context
IGC Pharma, Inc. operates in Alzheimer's disease therapeutics.
Key facts
Founded: N/A · Headquarters: Potomac, US · Employees: N/A · Revenue: N/A · Market cap: N/A